Creatine’s Double-Edged Cancer Twist

A cheap supplement sitting in gym bags worldwide may be quietly powering the immune cells your body needs to fight cancer — and UCLA researchers now have the lab data to back that up.

Story Snapshot

A 2026 UCLA study found that creatine fuels dendritic cells — key immune fighters — and slowed tumor growth in mice with melanoma.
Creatine acts like a molecular battery, giving immune cells the energy they need to trigger a cancer-fighting response.
Earlier UCLA research showed creatine also powers killer T cells, and combining it with a common cancer drug wiped out tumors in most mice tested.
The science is real but early — no human trials exist yet, and one study found creatine may help certain aggressive cancers spread.

What UCLA Researchers Actually Found

A UCLA research team published a study in the journal iScience in 2026 showing that daily creatine injections significantly slowed tumor growth in mice with melanoma. The tumors didn’t just grow more slowly — the mice also showed more dendritic cells inside their tumors, and those cells were more active. Dendritic cells are the immune system’s scouts. They spot cancer, sound the alarm, and direct killer T cells to attack.

The team went further and tested creatine on human dendritic cells grown in a lab. Those cells showed stronger activation and did a better job presenting a tumor protein called NY-ESO-1 to T cells — the handoff that launches a full immune attack. That human cell finding matters. It moves the science one step closer to something that could work in an actual person.

Creatine as a Molecular Battery for Immune Cells

The researchers used mass spectrometry to figure out why creatine helps. When they removed the creatine transporter from dendritic cells, those cells had much lower levels of ATP — the fuel every cell runs on. Without enough ATP, a key immune signaling pathway called NF-kappa B broke down. That pathway is what tells immune cells to go into attack mode. Creatine, it turns out, keeps that engine running.

This wasn’t the first time UCLA found creatine helping immune cells fight cancer. A 2019 study in the Journal of Experimental Medicine showed creatine also powers killer CD8 T cells — the immune system’s front-line assassins. In that study, mice that couldn’t absorb creatine into their T cells were worse at fighting tumors. The ones that could absorb it did far better.

When Creatine Plus a Cancer Drug Erased Tumors

The 2019 study tested what happened when creatine was combined with a PD-1 blockade drug — the class of immunotherapy drugs that has already changed cancer treatment for millions of patients. The result was striking. Four out of five mice receiving both creatine and the drug completely eliminated their colon cancer tumors. Those mice stayed cancer-free for over three months. When researchers tried to give them cancer again, their immune systems fought it off. That kind of synergy is exactly what oncology researchers dream about finding.

The Real Complication You Need to Know

Here is where it gets complicated — and honest science demands you know this part. A 2021 study published in Cell Metabolism found that dietary creatine promoted the spread of colorectal and breast cancer in mice. It activated a signaling chain involving genes that help tumor cells migrate to new locations. That is the opposite of what the UCLA studies found. The difference likely comes down to context — tumor type, cancer stage, and how creatine interacts with specific biological pathways in each setting.

The UCLA researchers themselves were clear: this study was done in cells and mice, not people. No dietary or medical recommendations should come from it. The experimental approaches have not been tested in humans or approved by the Food and Drug Administration (FDA) as safe or effective. That is not a dismissal of the findings — it is the honest state of the science right now. Human trials have not happened yet.

Why This Still Matters Right Now

Creatine costs a few dollars a month. The immunotherapy drugs it may one day work alongside cost tens of thousands of dollars per treatment. That economic gap alone explains why this research deserves serious attention — and why it may face quiet resistance from corners of the pharmaceutical industry that profit from expensive cancer drugs. That is not a conspiracy theory; it is a straightforward conflict of interest worth naming.

The path forward is clear: human trials testing creatine alongside PD-1 blockade drugs in melanoma patients. Researchers also want to study whether adding creatine during the manufacturing of dendritic cell vaccines could make those vaccines more powerful. If even a fraction of the mouse results translate to humans, the implications for cancer treatment — and for patients — would be enormous. That is worth watching closely.